EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study

Teresa Battista iD, Lucia Gallo, Fabrizio Martora iD, Davide Fattore, Luca Potestio iD, Sara Cacciapuoti iD, Massimiliano Scalvenzi, Matteo Megna iD

Journal of Clinical Medicine · 27.03.2024 · 13 (7) · 1940

DOI: 10.3390/jcm13071940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.03.2024. Verfasst von Teresa Battista und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is now recognized that psoriasis plays a key role in the development of several comorbidities, such as cardiovascular disease, and metabolic syndrome. Some authors have hypothesized that patients with psoriasis may have an increased risk of developing certain types of cancer. The efficacy and safety of biologic drugs are well-documented in clinical trials and in real-life studies. However, there is limited evidence on the safety of the use of biologic treatments in cancer patients with psoriasis, and the use of this therapeutic class in patients with a pre-existing or concomitant malignancy is still debated.

Methods

We have conducted a retrospective observational study of a group of oncology patients with moderate-to-severe psoriasis treated with biologic therapy at the Dermatology Clinic of the University of Naples Federico II, during the period from 2016 to 2024. We included 20 adult patients; in 15 of them the diagnosis of neoplasm preceded the start of treatment biologic, while four of these patients had been diagnosed with cancer during the course of therapy biologics.

Results

The most represented neoplasms in our population were breast carcinoma, prostate carcinoma, thyroid carcinoma, and chronic lymphatic leukemia. Anti-IL17 drugs were the most frequently prescribed (47.7%), followed by anti-IL23p19 (36.8%), anti-IL-12/23 (10.5%) and anti-TNF alpha (5.26%). All patients showed improvement of psoriasis after starting the therapy.

Conclusions

Our experience supports the effectiveness and safety of biological therapy for psoriasis in patients with a history of cancer or recent onset neoplasia.

Schlagwörter

Stichwörter der Autor:innen

biologic therapycancerpsoriasis

Autor:innen und Institutionen

  • Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy.

ORCID-Profile: Teresa Battista, Fabrizio Martora, Luca Potestio, Sara Cacciapuoti, Matteo Megna

Zitieren

APA

Battista, T., Gallo, L., Martora, F., Fattore, D., Potestio, L., Cacciapuoti, S., Scalvenzi, M., & Megna, M. (2024). Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of Clinical Medicine, 13(7), 1940. https://doi.org/10.3390/jcm13071940

Vancouver

Battista T, Gallo L, Martora F, Fattore D, Potestio L, Cacciapuoti S, et al. Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of Clinical Medicine. 2024;13(7):1940. doi:10.3390/jcm13071940

BibTeX
@article{Battista2024,
  author = {Battista, Teresa and Gallo, Lucia and Martora, Fabrizio and Fattore, Davide and Potestio, Luca and Cacciapuoti, Sara and Scalvenzi, Massimiliano and Megna, Matteo},
  title = {Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {7},
  pages = {1940},
  doi = {10.3390/jcm13071940}
}
Kostenlos starten →